PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study linking mucus plugs and COPD mortality could help save lives

A retrospective analysis of patient data from the COPDGene study suggests that targeting mucus plugs could help prevent deaths from chronic obstructive pulmonary disease—the fourth leading cause of death in the United States

2023-05-21
(Press-News.org) A retrospective analysis of patient data from the COPDGene study suggests that targeting mucus plugs could help prevent deaths from chronic obstructive pulmonary disease—the fourth leading cause of death in the United States

Many patients with chronic obstructive pulmonary disease (COPD) experience airway-clogging mucus plugs, an accumulation of mucus in the lungs that can affect quality of life and lung functioning. A new study led by researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, has found that mucus plugs were also associated with greater mortality. The findings, published in  JAMA and presented simultaneously at the American Thoracic Society 2023 International Conference, could help doctors reduce the death toll of COPD, which is one of the most common and deadly respiratory diseases.

“As a chronic disease, COPD can’t be cured, but our findings suggest that using therapies to break up these mucus plugs could help improve outcomes for COPD patients, which is the next best thing,” said corresponding author Alejandro A. Diaz, MD MPH, an associate scientist in the Division of Pulmonary and Critical Care Medicine at the Brigham. “Mucus is something that we already know a lot about from a basic science standpoint, and there are also a lot of mucus-targeting therapies that either already exist or are in development for other diseases, so it’s an extremely promising target.”

COPD affects 15.9 million people in the United States and is the fourth leading cause of death. It most often occurs as a result of cigarette smoking or long-term exposure to air pollutants. The progression of COPD can be slowed by eliminating the exposure to these pollutants, but there is no way to cure the disease. And the standard therapeutic approach for COPD has gone largely unchanged for many years.

“For the last four decades we’ve had only two targets for COPD therapies –either promoting bronchial dilation, which means making the airways themselves wider, or reducing bronchial inflammation,” said Diaz. “This is telling us that there may be more we can do about this disease than we realized before.”

The current study was an observational retrospective analysis of data from the Genetic Epidemiology of COPD (COPDGene) study, a large-scale clinical study that aimed to investigating the underlying genetic risk factors of COPD. The study included over 10,000 participants, recruited between 2007 and 2011, and included people with COPD at different stages, from the mildest to the most severe.

For this new observational study, the researchers looked at data from over 4,000 of these patients. To determine which patients had mucus plugs, the researchers analyzed chest CT scans from the patients, taken at their first visit to the clinic. Performing CT scans on all patients regardless of their self-reported symptoms allowed the researchers to find mucus plugs even in patients who did not feel sick.

“Creating mucus is a normal part of the body’s immune response, but usually we cough it up as we’re getting better,” said Diaz. “COPD causes the body to produce too much mucus and makes it harder to clear out, so you end up with these mucus plugs that aren’t strongly correlated with any specific symptoms and can go undetected.”

The researchers found that over the course of the study, the mortality rate for COPD patients with no detectable mucus plugs was 34 percent. For patients with mucus plugs in up to two lung segments, the mortality rate jumped to 46.7 percent. For patients with plugs in three or more lung segments, the mortality rate was 54.1 percent.

“The data show a compelling association between the accumulation of these mucus plugs and overall mortality, but we don’t know anything about what’s driving it yet,” adds Diaz.

Because mucus is a known therapeutic target for other diseases, the researchers are next planning to test existing mucus-targeting therapies in people with COPD to determine if treating the mucus plugs could have a positive impact on patient outcomes.

In the meantime, the research demonstrates that there are factors affecting COPD mortality that we still know little about, and that not all these factors will necessarily appear as symptoms for the patient.

“The fact that these mucus plugs were associated with mortality across different disease phases tells us that there are aspects of COPD progression that can be picked up by a CT scan even if they’re not felt by the patient,” said Diaz. “It’s not so simple as to say every person with COPD needs to run out and get a CT scan tomorrow, but it’s something for clinicians to consider when they’re working with their patients.”

Disclosures: Alejandro A Diaz reports speaker fees from Boehringer Ingelheim and a pending USPT patent. Victor Kim reports personal fees from Gala Therapeutics, ABIM Critical Care Testwriting Committee, AstraZeneca, and Boehringer Ingelheim. Meilan K. Han has received personal fees from Boehringer Ingelheim, AstraZeneca and research support from Novartis and Sunovio. George R. Washko reports grants and other support from Boehringer Ingelheim, Quantitative Imaging Solutions, PulmonX, Janssen Pharmaceuticals, Vertex, and CSLE Berhing, and his spouse is an employee of Biogen. Raúl San José Estépar reports personal fees from Chiesi, Leuko Labs, Lung Biotechnology, Boehringer Ingelheim and is a founder and equity holder of Quantitative Image Solutions.

Funding: The COPDGene project was supported by Award Number U01 HL089897 and Award Number U01HL089856 from the National Heart, Lung, and Blood Institute. The COPD Foundation also supports the COPDGene® project through contributions to an Industry Advisory Board comprised of AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, and Sunovion. Dr. Diaz is supported by funding from the US National Heart, Lung, and Blood Institute (R01-HL133137, R01-HL149861, R01-HL164824) and the Brigham and Women’s Hospital Minority Faculty Career Development Award.

Paper cited: Diaz, AA et al. “Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease” JAMA DOI: 10.1001/jama.2023.2065

END


ELSE PRESS RELEASES FROM THIS DATE:

Sacubitril/valsartan shows benefit in heart failure with ejection fraction above 40%

2023-05-21
Prague, Czechia – 21 May 2023:  Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilisation for worsening heart failure in patients with an ejection fraction (EF) above 40%, according to late breaking science presented today at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC),1 and published in the Journal of the American College of Cardiology. Principal investigator Dr. Robert Mentz of Duke University Medical Center, Durham, US said: “These data add to the evidence supporting a potential treatment benefit of sacubitril/valsartan ...

New device gently moves esophagus, making heart ablations safer, study found

New device gently moves esophagus, making heart ablations safer, study found
2023-05-21
A new device invented with the help of an electrophysiologist at The Ohio State University Wexner Medical Center makes a heart procedure safer for patients suffering from atrial fibrillation (AFib), a common irregular heart rhythm. AFib affects millions of people worldwide and greatly increases their risk of stroke and heart failure. To treat AFib, doctors use cardiac ablation to help restore the heart’s rhythm. Heat or cold energy delivered through a catheter destroys the heart tissue causing rapid and irregular heartbeats. ...

Society for Cardiovascular Angiography & Interventions names George D. Dangas, MD, MSCAI, President for 2023-24

2023-05-21
PHOENIX (May 20, 2023) – George D. Dangas, MD, PhD, MSCAI, Professor of Medicine (Cardiology and Surgery), and Director of Cardiovascular Innovation at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine of Mount Sinai in New York City, and Chief of Cardiology at Mount Sinai Queens assumed the office of president of the Society for Cardiovascular Angiography & Interventions (SCAI) today during the closing ceremonies at the SCAI 2023 Scientific Sessions in Phoenix, AZ. Dr. Dangas is an authoritative voice in the performance of nonsurgical cardiovascular and valve interventions using both established ...

SCAI announces 2023-24 SCAI-WIN CHIP Fellowship Recipient

2023-05-21
PHOENIX (May 20, 2023) – Njambi Mathenge, MD, MPH, an interventional cardiology fellow at the Massachusetts General Hospital has been selected as the recipient of the SCAI-Women in Innovations (SCAI-WIN) CHIP Fellowship, the Society for Cardiovascular Angiography and Interventions announced today. The $115,000 fellowship opportunity was made possible by support from Abiomed (founding supporter), Boston Scientific, Medtronic, and Shockwave Medical, Inc., and is offered to interventional cardiology (IC) fellows or practicing interventional cardiologists interested in ...

SCAI announces new award recognizing the contributions of early career interventional cardiologists

2023-05-21
PHOENIX (May 20, 2023) – Today during the SCAI 2023 Scientific Sessions, thirty early-career interventional cardiologists were the inaugural recipients of a newly created award highlighting excellence in interventional cardiology. 30 in Their 30’s is a new recognition program created by the Society for Cardiovascular Angiography & Interventions (SCAI) for early-career members for their proven leadership and demonstration of SCAI’s core values. 30 in Their 30’s recognizes the best and brightest young professionals in interventional cardiology. This award ...

Society for Cardiovascular Angiography and Interventions bestows highest designation ranking to leading interventional cardiologists

2023-05-21
PHOENIX (May 20, 2023) – Today, the Society for Cardiovascular Angiography & Interventions (SCAI) announced its 2023 Master Interventionalists of SCAI (MSCAI) designation recipients during the SCAI 2023 Scientific Sessions in Phoenix. The MSCAI designation is awarded to individuals who have demonstrated excellence in invasive/interventional cardiology over the course of their career and for their commitment to the highest levels of clinical care, innovation, publication, and teaching. This year’s MSCAI designations were awarded to the following group of outstanding interventionalists: David ...

HRS, APHRS, and LAHRS release cardiac physiological pacing guideline

2023-05-20
New Orleans, May 20, 2023 – Today, the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS) released a new clinical practice guideline on cardiac physiologic pacing (CPP) strategies to restore ventricular synchrony and improve cardiac performance. The 2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure is intended to provide guidance to clinical cardiac electrophysiologists, cardiologists, and other clinicians on the use of CPP, which includes cardiac resynchronization therapy and conduction system pacing, in patients ...

Tokyo Tech and HPE collaborate to build the next generation TSUBAME4.0 supercomputer for artificial intelligence, scientific research, and innovation

Tokyo Tech and HPE collaborate to build the next generation TSUBAME4.0 supercomputer for artificial intelligence, scientific research, and innovation
2023-05-20
Tokyo Institute of Technology (Tokyo Tech) Global Scientific Information and Computing Center (GSIC) and Hewlett Packard Enterprise (NYSE: HPE) announced to build its next-generation supercomputer, TSUBAME4.0, to accelerate AI-driven scientific discovery in medicine, materials science, climate research, and turbulence in urban environments. Tokyo Tech is one of the world's leading universities in science and technology. With the TSUBAME4.0 supercomputer, users will have the ability to train ...

Heart attack patients with strong legs have better prognosis

2023-05-20
Prague, Czechia – 20 May 2023:  People with strong legs are less likely to develop heart failure after a heart attack, according to research presented today at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC).1 Myocardial infarction is the most common cause of heart failure,2 with around 6–9% of heart attack patients going on to develop the condition.3,4 Previous research has shown that having strong quadriceps is associated with a lower risk of death in patients with coronary artery disease.5 This study tested ...

Remote monitoring reduces heart failure hospitalizations and improves quality of life

2023-05-20
Prague, Czechia – 20 May 2023:  The first investigator-initiated study of remote pulmonary artery pressure monitoring has found that it improves quality of life and reduces heart failure hospitalisations in patients with chronic heart failure. The findings are presented today in a late breaking science session at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC),1 and published in The Lancet. Principal investigator Dr. Jasper Brugts of Erasmus University Medical Centre, ...

LAST 30 PRESS RELEASES:

Call for papers: 14th Asia-Pacific Conference on Transportation and the Environment (APTE 2025)

A novel disturbance rejection optimal guidance method for enhancing precision landing performance of reusable rockets

New scan method unveils lung function secrets

Searching for hidden medieval stories from the island of the Sagas

Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model

Neuroscience leader reveals oxytocin's crucial role beyond the 'love hormone' label

Twelve questions to ask your doctor for better brain health in the new year

Microelectronics Science Research Centers to lead charge on next-generation designs and prototypes

Study identifies genetic cause for yellow nail syndrome

New drug to prevent migraine may start working right away

Good news for people with MS: COVID-19 infection not tied to worsening symptoms

Department of Energy announces $179 million for Microelectronics Science Research Centers

Human-related activities continue to threaten global climate and productivity

Public shows greater acceptance of RSV vaccine as vaccine hesitancy appears to have plateaued

Unraveling the power and influence of language

Gene editing tool reduces Alzheimer’s plaque precursor in mice

TNF inhibitors prevent complications in kids with Crohn's disease, recommended as first-line therapies

Twisted Edison: Bright, elliptically polarized incandescent light

Structural cell protein also directly regulates gene transcription

Breaking boundaries: Researchers isolate quantum coherence in classical light systems

Brain map clarifies neuronal connectivity behind motor function

Researchers find compromised indoor air in homes following Marshall Fire

Months after Colorado's Marshall Fire, residents of surviving homes reported health symptoms, poor air quality

Identification of chemical constituents and blood-absorbed components of Shenqi Fuzheng extract based on UPLC-triple-TOF/MS technology

'Glass fences' hinder Japanese female faculty in international research, study finds

Vector winds forecast by numerical weather prediction models still in need of optimization

New research identifies key cellular mechanism driving Alzheimer’s disease

Trends in buprenorphine dispensing among adolescents and young adults in the US

Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility

Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity

[Press-News.org] Study linking mucus plugs and COPD mortality could help save lives
A retrospective analysis of patient data from the COPDGene study suggests that targeting mucus plugs could help prevent deaths from chronic obstructive pulmonary disease—the fourth leading cause of death in the United States